INTRODUCTION: Anaplastic lymphoma kinase (ALK) rearrangements are present in an important subset of non-small-cell lung cancer (NSCLC) and predict for response to the tyrosine kinase inhibitor crizotinib. In this study, we evaluated the yet unknown frequency and functional role of ALK splicing isoforms in NSCLC. METHODS: We analyzed 270 cases of NSCLC for ALK kinase domain splicing aberrations and in addition generated constructs with full-length echinoderm microtubule-associated protein-like 4 (EML4)-ALK (E13;A20) and a splicing isoform. RESULTS: Splicing isoforms of the kinase domain of ALK-including complete skipping of exon 23 (ALKdel23, ALK p.I1171fs*42) and exon 27 (ALKdel27, ALK p.T1312fs*0)-were identified in 11.1% (30 of 270 cases) of NSCLC, and these changes coexisted with ALK rearrangements, KRAS mutations, and EGFR mutations. ALK splicing isoforms were observed with full-length EML4-ALK in crizotinib-naive and treated NSCLCs. ALK T1312fs*0 was unable to render cells solely dependent on ALK signaling. Unlike EML4-ALK and EML4-ALK p.L1196M, EML4-ALK T1312fs*0 did not autophosphorylate ALK or other phosphotyrosine sites. Coexpression of equal amounts of EML4-ALK T1312fs*0 and EML4-ALK did not result in resistance to crizotinib, whereas coexpression of EML4-ALK L1196M with EML4-ALK resulted in resistance to inhibition of ALK by crizotinib. CONCLUSIONS: ALK kinase splicing isoforms were present in NSCLC and even if translated seemed to be nonfunctional variants of ALK.
INTRODUCTION:Anaplastic lymphoma kinase (ALK) rearrangements are present in an important subset of non-small-cell lung cancer (NSCLC) and predict for response to the tyrosine kinase inhibitor crizotinib. In this study, we evaluated the yet unknown frequency and functional role of ALK splicing isoforms in NSCLC. METHODS: We analyzed 270 cases of NSCLC for ALK kinase domain splicing aberrations and in addition generated constructs with full-length echinoderm microtubule-associated protein-like 4 (EML4)-ALK (E13;A20) and a splicing isoform. RESULTS: Splicing isoforms of the kinase domain of ALK-including complete skipping of exon 23 (ALKdel23, ALKp.I1171fs*42) and exon 27 (ALKdel27, ALKp.T1312fs*0)-were identified in 11.1% (30 of 270 cases) of NSCLC, and these changes coexisted with ALK rearrangements, KRAS mutations, and EGFR mutations. ALK splicing isoforms were observed with full-length EML4-ALK in crizotinib-naive and treated NSCLCs. ALKT1312fs*0 was unable to render cells solely dependent on ALK signaling. Unlike EML4-ALK and EML4-ALKp.L1196M, EML4-ALKT1312fs*0 did not autophosphorylate ALK or other phosphotyrosine sites. Coexpression of equal amounts of EML4-ALKT1312fs*0 and EML4-ALK did not result in resistance to crizotinib, whereas coexpression of EML4-ALKL1196M with EML4-ALK resulted in resistance to inhibition of ALK by crizotinib. CONCLUSIONS:ALK kinase splicing isoforms were present in NSCLC and even if translated seemed to be nonfunctional variants of ALK.
Authors: Daniel B Costa; Kim-Son H Nguyen; Byoung C Cho; Lecia V Sequist; David M Jackman; Gregory J Riely; Beow Y Yeap; Balázs Halmos; Joo H Kim; Pasi A Jänne; Mark S Huberman; William Pao; Daniel G Tenen; Susumu Kobayashi Journal: Clin Cancer Res Date: 2008-11-01 Impact factor: 12.531
Authors: Jussi P Koivunen; Craig Mermel; Kreshnik Zejnullahu; Carly Murphy; Eugene Lifshits; Alison J Holmes; Hwan Geun Choi; Jhingook Kim; Derek Chiang; Roman Thomas; Jinseon Lee; William G Richards; David J Sugarbaker; Christopher Ducko; Neal Lindeman; J Paul Marcoux; Jeffrey A Engelman; Nathanael S Gray; Charles Lee; Matthew Meyerson; Pasi A Jänne Journal: Clin Cancer Res Date: 2008-07-01 Impact factor: 12.531
Authors: Ultan McDermott; A John Iafrate; Nathanael S Gray; Toshi Shioda; Marie Classon; Shyamala Maheswaran; Wenjun Zhou; Hwan Geun Choi; Shannon L Smith; Lori Dowell; Lindsey E Ulkus; Georgiana Kuhlmann; Patricia Greninger; James G Christensen; Daniel A Haber; Jeffrey Settleman Journal: Cancer Res Date: 2008-05-01 Impact factor: 12.701
Authors: Issan Yee San Tam; Lap Ping Chung; Wai Sing Suen; Elaine Wang; May C M Wong; Kok Keung Ho; Wah Kit Lam; Shui Wah Chiu; Luc Girard; John D Minna; Adi F Gazdar; Maria P Wong Journal: Clin Cancer Res Date: 2006-03-01 Impact factor: 12.531
Authors: Neal I Lindeman; Philip T Cagle; Mary Beth Beasley; Dhananjay Arun Chitale; Sanja Dacic; Giuseppe Giaccone; Robert Brian Jenkins; David J Kwiatkowski; Juan-Sebastian Saldivar; Jeremy Squire; Erik Thunnissen; Marc Ladanyi Journal: J Thorac Oncol Date: 2013-07 Impact factor: 15.609
Authors: Antonio R Lucena-Araujo; Jason P Moran; Paul A VanderLaan; Dora Dias-Santagata; Erik Folch; Adnan Majid; Michael S Kent; Sidharta P Gangadharan; Deepa Rangachari; Mark S Huberman; Susumu S Kobayashi; Daniel B Costa Journal: Lung Cancer Date: 2016-06-14 Impact factor: 5.705
Authors: David Cl Lam; Susan Y Luo; Wen Deng; Johnny Sh Kwan; Jaime Rodriguez-Canales; Annie Lm Cheung; Grace Hw Cheng; Chi-Ho Lin; Ignacio I Wistuba; Pak C Sham; Thomas Sk Wan; Sai-Wah Tsao Journal: Onco Targets Ther Date: 2015-01-16 Impact factor: 4.147